Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $9.8333.
BDTX has been the topic of several recent research reports. BTIG Research boosted their target price on Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wall Street Zen cut Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen reiterated a “buy” rating on shares of Black Diamond Therapeutics in a research report on Friday, May 22nd. Jefferies Financial Group raised Black Diamond Therapeutics to a “strong-buy” rating in a research note on Thursday, April 23rd. Finally, HC Wainwright restated a “buy” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd.
Get Our Latest Stock Report on BDTX
Black Diamond Therapeutics Trading Up 0.5%
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. On average, analysts expect that Black Diamond Therapeutics will post -0.6 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of BDTX. Geode Capital Management LLC raised its position in Black Diamond Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 505,780 shares of the company’s stock valued at $1,229,000 after purchasing an additional 5,257 shares during the period. Engineers Gate Manager LP lifted its stake in shares of Black Diamond Therapeutics by 48.9% in the 4th quarter. Engineers Gate Manager LP now owns 19,701 shares of the company’s stock valued at $48,000 after purchasing an additional 6,469 shares during the last quarter. Kathmere Capital Management LLC grew its holdings in shares of Black Diamond Therapeutics by 31.0% during the 4th quarter. Kathmere Capital Management LLC now owns 31,822 shares of the company’s stock worth $77,000 after purchasing an additional 7,539 shares during the period. Bank of America Corp DE grew its holdings in shares of Black Diamond Therapeutics by 22.5% during the 3rd quarter. Bank of America Corp DE now owns 43,359 shares of the company’s stock worth $164,000 after purchasing an additional 7,972 shares during the period. Finally, Cerity Partners LLC acquired a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth about $26,000. Institutional investors and hedge funds own 95.47% of the company’s stock.
Black Diamond Therapeutics Company Profile
Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.
The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.
Featured Stories
- Five stocks we like better than Black Diamond Therapeutics
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
